Details.
Development of cost-effectiveness models for pharmaceutical interventions and medical devices, from early strategic planning through to reimbursement applications and post-launch value demonstration. Approaches include decision analytic models, cohort models, patient-level simulations, Markov models, probabilistic and deterministic methodologies, acceptability curves, and net health or net monetary benefit analyses. Model review and critique services are also provided for models developed by third parties or health technology assessment agencies.
